ReviewNature reviews. Gastroenterology & hepatology2013
The genetics of NAFLD.
Review in Nature reviews. Gastroenterology & hepatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 168 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
168 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genetic polymorphisms associated with nonalcoholic fatty liver disease in Uyghur population: a case-control study and meta-analysis.Lipids in health and disease · 2019Pooled it
- Subtyping metabolic dysfunction-associated steatotic liver disease using electronic health record-linked genomic cohorts reveals diverse etiologies and progression.Nature communications · 2026Article
- Dyslipidaemia and hepatic steatosis: mechanisms and implications for lipid-lowering therapy.Nature reviews. Cardiology · 2026Review
- Prediction of trajectories and outcomes in early-stage metabolic dysfunction-associated steatotic liver disease: a narrative review.EClinicalMedicine · 2026Review
- Application of Multivariate Adaptive Regression Splines to Estimate Fatty Liver Index in Healthy Young Taiwanese Men.Diagnostics (Basel, Switzerland) · 2026Article
- GCN5 drives MASLD progression through LXRα/SREBP1c signaling pathway-mediated de novo lipogenesis.Nature communications · 2026Article
- Modeling fatty liver disease and progression with stem cell derived hepatocytes.Scientific reports · 2026Article
- Differentially expressed genes and therapeutic targets for nonalcoholic fatty liver disease from transcriptomic techniques.Medicine · 2025Article
- Prevalence of advanced fibrosis risk using FIB-4 in patients with type 2 diabetes and its associated factors: a cross-sectional study in a primary care unit of a university hospital in Southern Thailand.BMC primary care · 2025Article
- MASLD development: From molecular pathogenesis toward therapeutic strategies.Chinese medical journal · 2025Review
- Liver disease trends in the Asia-Pacific region for the next 50 years.Clinical and molecular hepatology · 2025Review
- Parental liver disease mortality is associated with unfavorable outcomes in patients with alcohol-associated hepatitis.Hepatology communications · 2025Observational
- Association between single nucleotide polymorphisms in PNPLA3, TM6SF2 and MBOAT7 genes and markers of cancer aggressiveness in a Sri Lankan NASH-related HCC cohort.BMC gastroenterology · 2025Article
- ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASH.Journal of hepatology · 2025Article
- A proteome-wide association study reveals novel plasma proteins as potential therapeutic targets for metabolic dysfunction-associated steatotic liver disease.Frontiers in endocrinology · 2025Article
- Role of genetic variants and DNA methylation of lipid metabolism-related genes in metabolic dysfunction-associated steatotic liver disease.Frontiers in physiology · 2025Review
- Causal relationships between three plasma proteins and non-alcoholic fatty liver disease, mediated by Epstein-Barr virus EA-D antibody levels: a mendelian randomization study.Scientific reports · 2024Article
- Review
- Metabolic Dysfunction-Associated Steatotic Liver Disease and Polycystic Ovary Syndrome: A Complex Interplay.Journal of clinical medicine · 2024Review
- Myeloid AMPK signaling restricts fibrosis but is not required for metformin improvements during CDAHFD-induced NASH in mice.Journal of lipid research · 2024Article
108 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NAFLD is a disease spectrum ranging from simple steatosis, through steatohepatitis to fibrosis and, ultimately, cirrhosis. This condition is characterized by considerable interpatient variability in terms of severity and rate of progression: although a substantial proportion of the population is at risk of progressive disease, only a minority experience associated morbidity. As such, NAFLD is best considered a complex disease trait resulting from environmental exposures acting on a susceptible polygenic background and comprising multiple independent modifiers. Much ongoing research is focused on identifying the genetic factors that contribute to NAFLD pathogenesis. This Review describes the current status of the field, discussing specific genetic and epigenetic modifiers, including the mechanisms through which genes identified by genome-wide association studies, including PNPLA3, influence disease progression.
Indexed as
Identifiers
24061205What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.